Clarisond

Clarisond, Inc. is a Salem, NH-based startup focusing on commercializing technology to enhance the clarity of medical ultrasound images, with a particular emphasis on breast cancer screening. The company was founded in 2013 and operates in the Health Care, Information Technology, and Medical Devices sectors.

Currently, Clarisond holds a Phase II SBIR grant from the National Science Foundation to develop and bring its imaging technology to market, acknowledging the need for alternative imaging modalities in women with mammographically dense breast tissue.

With ultrasound imaging showing sensitivity to suspect lesions but plagued by a high false positive rate, Clarisond's technology aims to enhance the quality of breast ultrasound imaging, improving sensitivity to early stage lesions and decreasing false positives, ultimately addressing the need for alternative imaging modalities. While the focus is initially on breast imaging, the technology is broadly applicable to general ultrasound imaging, offering a wide market potential.

As this revolutionary technology continues to develop, it presents an attractive investment opportunity within the rapidly growing health tech sector, potentially offering significant positive impact both in healthcare outcomes and market potential.